News
MRK
120.31
-0.44%
-0.53
Trump Trade: President says Iran war will still take weeks
TipRanks · 54m ago
Merck granted EU approval of Keytruda combo in ovarian cancer
Seeking Alpha · 2h ago
Adagene announces results from the latest data cut of muzastotug study
TipRanks · 3h ago
Merck initiates Phase 2b/3 trial evaluating MK-8748
TipRanks · 3h ago
Merck’s Keytruda in combination approved in EU for ovarian carcinoma
TipRanks · 3h ago
Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma In Adults
Benzinga · 4h ago
Trump administration readying new pharmaceutical tariffs, FT reports
TipRanks · 4h ago
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Barchart · 9h ago
No deal yet? Trump readies 100% tariffs on select drugmakers - report
Seeking Alpha · 10h ago
Lilly CEO says company opposes codification of Trump drug pricing deals
Seeking Alpha · 17h ago
Merck Taps Infinimmune AI Antibodies To Support Long Term Growth Narrative
Simply Wall St · 18h ago
Healthcare among laggards in Q1; MRNA and DVA lead gainers while HUM drags
Seeking Alpha · 22h ago
Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz
Benzinga · 1d ago
Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs
Benzinga · 1d ago
Press Release: Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
Dow Jones · 1d ago
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
TipRanks · 1d ago
FDA ready to allow compounding pharmacies to make injectable peptides - report
Seeking Alpha · 1d ago
Is Trump to blame for delayed drug launches in Europe
Seeking Alpha · 1d ago
April Dogs Of The Dow: One To Buy
Seeking Alpha · 1d ago
Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick
NASDAQ · 1d ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.